High impact information on Sexual Dysfunctions, Psychological

• Therefore, arginase is a potential therapeutic target for the treatment of sexual arousal disorders in men and women [1].
• We studied the efficacy and safety of transdermal testosterone in treating hypoactive sexual desire disorder in surgically menopausal women [2].
• Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women [3].
• Therefore, arginase II is a potential target for the treatment of male and female sexual arousal disorders [4].
• For women with FSAD without concomitant hypoactive sexual desire disorder (HSDD) sildenafil was associated with significantly greater improvement in 5 of 6 FIEI items compared with placebo (p <0.02) [5].

Chemical compound and disease context of Sexual Dysfunctions, Psychological

• Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study [5].
• OBJECTIVE: To assess the efficacy and safety of a 300 mug/d testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women on concomitant estrogen therapy [6].
• At various time points, worsened sexual functioning, sexual desire disorder, sexual arousal disorder, and dissatisfaction with sexual functioning in those satistied at baseline were more frequently associated with fluoxetine treatment than with bupropion SR or placebo [7].
• A similar pattern of psychosexual disorders has been observed after long-term treatment with levodopa therapy in four male parkinsonian patients treated with apomorphine for severe on-off motor fluctuations [8].
• The use of DHEA therapy may also be discussed in women of any age when a trial of androgen supplementation seems justified because of the existence of an inhibited sexual desire or a sexual arousal disorder associated with documented androgen deficiency [9].

Biological context of Sexual Dysfunctions, Psychological

• CONCLUSIONS: The 300-microg/d testosterone patch increased sexual desire and frequency of satisfying sexual activity and was well tolerated in women who developed hypoactive sexual desire disorder after surgical menopause [2].
• Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder [10].
• The sexual medicine community watched with interest as the Food and Drug Administration (FDA) considered the Proctor & Gamble new drug application for Intrinsa (a testosterone patch for hypoactive sexual desire disorder for women who had undergone surgical castration via bilateral oophorectomy) [11].

Gene context of Sexual Dysfunctions, Psychological

• Respondents indicate a lack of ability as well as discomfort with several areas of sexuality, notably frigidity and homosexuality [12].
• In addition, recent experimental and clinical evidence for a postulated feedback mechanism for prolactin and its implications for orgasmic disorders are discussed [13].
• As a consequence, the efficacy and safety of the PDE5 inhibitor sildenafil in the treatment of symptoms of female sexual dysfunction (FSD), including female sexual arousal disorders (FSAD), have been evaluated [14].

References